BioXcel Therapeutics: Analysts Update Price Target to $16.75, Mizuho Raises Estimate to $390M.

BioXcel Therapeutics' latest price target update maintains a fair value of $16.75 per share, with analysts citing stronger visibility in long-term revenue potential after the SERENITY At Home data. However, funding and execution uncertainties limit the stock's valuation. Mizuho doubled its price target to $4 from $2, reflecting increased confidence in BXCL501's commercial potential. Despite the higher target, Mizuho maintained a Neutral rating, highlighting uncertainty around BioXcel's financing plans.